Fig. 5From: Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular DystrophyNaproxcinod significantly reduces fibrosis in diaphragm of mdx mice. Quantification of fibrosis content assessed by Masson’s Trichrome staining in the diaphragm of mdx mice treated with vehicle (black bar), 30 mg/kg naproxcinod (white bar), or 20 mg/kg naproxen (grey bar) following 6 months of treatment. a Representative histological images of the diaphragm and b quantification of fibrotic area, expressed as a percentage of muscle cross section. Data are presented as mean ± SEM. *represents the comparison between vehicle and treatment groups. #represents the comparison versus the naproxen-treated group. One-way ANOVA followed by Tukey post-hoc test. ** P < 0.01; # P < 0.05. N = 4-5 mice/group. Bar = 100 μmBack to article page